299 results match your criteria Renal Oncocytoma Imaging

Laparoscopic resection of large oncocytoma with metaplastic ossification: Case report and video.

Urol Case Rep 2022 Sep 18;44:102112. Epub 2022 May 18.

Urology Department of Hospital de Clínicas de Porto Alegre, Rio Grande do Sul, Brazil.

Renal oncocytoma (RO) represents about 7% of kidney tumors. They usually behave in a benign fashion, with a slow-growth rate. Patients are often asymptomatic and the tumour is found incidentally on imaging. Read More

View Article and Full-Text PDF
September 2022

Renal oncocytoma: a challenging diagnosis.

Curr Opin Oncol 2022 05;34(3):243-252

University of Maryland Greenebaum Comprehensive Cancer Center.

Purpose Of Review: The aim of the review is to provide an update on the current and evolving approaches to diagnosing the challenging clinical entity of renal oncocytoma.

Recent Findings: Renal oncocytoma is being increasingly recognized among patients with renal masses, and it can be found in up to 50% of benign small renal masses (SRMs) less than 4 cm. Renal oncocytomas have benign clinical biology but distinguishing them from some of the other renal masses with more malignant potential can be challenging due to overlapping imaging, histologic, and immunophenotypic characteristics. Read More

View Article and Full-Text PDF

Apparent Diffusion Coefficient Map-Based Texture Analysis for the Differentiation of Chromophobe Renal Cell Carcinoma from Renal Oncocytoma.

Diagnostics (Basel) 2022 Mar 26;12(4). Epub 2022 Mar 26.

Department of Urology, Tokyo Medical and Dental University Graduate School, 1-5-45 Yushima, Bunkyo-Ku, Tokyo 113-8510, Japan.

Preoperative imaging differentiation between ChRCC and RO is difficult with conventional subjective evaluation, and the development of quantitative analysis is a clinical challenge. Forty-nine patients underwent partial or radical nephrectomy preceded by MRI and followed by pathological diagnosis with ChRCC or RO (ChRCC: = 41, RO: = 8). The whole-lesion volume of interest was set on apparent diffusion coefficient (ADC) maps of 1. Read More

View Article and Full-Text PDF

Imaging of the Pancreas in New-Onset Diabetes: A Prospective Pilot Study.

Clin Transl Gastroenterol 2022 Jun 1;13(6):e00478. Epub 2022 Jun 1.

Department of Radiology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, USA.

Introduction: The aim of this study was to assess the feasibility of cross-sectional imaging for detection of pancreatic cancer (PDAC) in patients with new-onset hyperglycemia and diabetes (NOD).

Methods: We conducted a prospective pilot study from November 2018 to March 2020 within an integrated health system. Patients aged 50-85 years with newly elevated glycemic parameters without a history of diabetes were invited to complete a 3-phase contrast-enhanced computed tomography pancreas protocol scan while participating in the Prospective Study to Establish a NOD Cohort. Read More

View Article and Full-Text PDF

A Rare Case of Synchronous Oncocytoma and Angiomyolipoma of the Kidney.

Am J Case Rep 2022 Mar 1;23:e935407. Epub 2022 Mar 1.

Department of Pathology and Laboratory Medicine, East Carolina University/Vidant Medical Center, Greenville, NC, USA.

BACKGROUND The co-occurrence of renal oncocytoma and angiomyolipoma is exceedingly rare. To date, 17 such cases have been reported in the literature. This report describes a unique case of that association that presented as a single renal mass on imaging. Read More

View Article and Full-Text PDF

Radiomics improves the utility of ADC for differentiation between renal oncocytoma and chromophobe renal cell carcinoma: Preliminary findings.

Actas Urol Esp (Engl Ed) 2022 04 22;46(3):167-177. Epub 2022 Feb 22.

Istanbul Medeniyet University, Faculty of Medicine, Department of Radiology, Istanbul, Turkey.

Objective: Differentiation between renal oncocytoma (RON) and chromophobe renal cell carcinoma (chRCC) remains challenging. We aimed to assess the accurate apparent diffusion coefficient (ADC) radiomics features in differentiating these tumors.

Materials And Methods: This single-center retrospective study included 14 patients with histopathologically proven RON (n = 6) and chRCC (n = 8) who underwent magnetic resonance imaging. Read More

View Article and Full-Text PDF

Ultrasonography findings for the diagnosis of renal oncocytoma.

J Med Ultrason (2001) 2022 Apr 27;49(2):211-216. Epub 2022 Jan 27.

Department of Ultrasound, China-Japan Union Hospital of Jilin University, No. 126 Xiantai Street, Changchun, 130033, Jilin Province, China.

Renal oncocytomas are rare benign epithelial tumors of the kidney. However, they are easily misdiagnosed as renal cancers, resulting in unnecessary radical nephrectomy. This review summarizes the use of ultrasound for the diagnosis of renal oncocytomas. Read More

View Article and Full-Text PDF

High-Resolution Ultrasonography of Renal Oncocytoma Presenting with Symptomatic Hematuria and Urinary Bladder Clot Retention-A Rare Occurrence.

Reddy Ravikanth

J Kidney Cancer VHL 2022 1;9(1):15-18. Epub 2022 Jan 1.

Department of Radiology, St. John's Hospital, Bengaluru, India.

Renal oncocytomas are asymptomatic, benign tumors often encountered incidentally on various imaging modalities. Renal oncocytomas comprise 5-7% of primary renal neoplasms and are derived from cells of the distal renal tubule. We present a case report of renal oncocytoma in a 22-year-old male having right-sided flank pain and symptomatic gross hematuria with a giant urinary bladder clot retention. Read More

View Article and Full-Text PDF
January 2022

A CT-based radiomics nomogram for differentiation of renal oncocytoma and chromophobe renal cell carcinoma with a central scar-matched study.

Br J Radiol 2022 Jan 4;95(1129):20210534. Epub 2021 Nov 4.

Department of Radiology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.

Objective: Pre-operative differentiation between renal oncocytoma (RO) and chromophobe renal cell carcinoma (chRCC) is critical due to their different clinical behavior and different clinical treatment decisions. The aim of this study was to develop and validate a CT-based radiomics nomogram for the pre-operative differentiation of RO from chRCC.

Methods: A total of 141 patients (84 in training data set and 57 in external validation data set) with ROs ( = 47) or chRCCs ( = 94) were included. Read More

View Article and Full-Text PDF
January 2022

Symptomatic giant renal oncocytoma with an incidental papillary adenoma.

Urol Case Rep 2021 Nov 21;39:101799. Epub 2021 Aug 21.

Chelsea and Westminister Hospital, London, SW10 9NH, UK.

Renal oncocytomas are benign, slow-growing tumours accounting for 3-7% of all solid renal neoplasms. These tumours tend to be small, unilateral and asymptomatic and are often discovered incidentally on imaging. Large oncocytomas are rare and can be difficult to distinguish from renal cell carcinoma based off clinical findings or imaging characteristics alone. Read More

View Article and Full-Text PDF
November 2021

Simultaneous adrenal tuberculosis and renal oncocytoma mimicking malignant masses incidentally detected by F-FDG PET/CT in a patient with lymphoma.

Eur J Nucl Med Mol Imaging 2022 01 24;49(2):777-778. Epub 2021 Aug 24.

Department of Nuclear Medicine and PET Center, The Second Affiliated Hospital of Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, 310009, Zhejiang, China.

View Article and Full-Text PDF
January 2022

A CT-based radiomics nomogram for differentiation of small masses (< 4 cm) of renal oncocytoma from clear cell renal cell carcinoma.

Abdom Radiol (NY) 2021 11 15;46(11):5240-5249. Epub 2021 Jul 15.

Department of Radiology, the Affiliated Hospital of Qingdao University, Qingdao, China.

Purpose: Renal oncocytoma (RO) is the most commonly resected benign renal tumor because of misdiagnosis as renal cell carcinoma. This misdiagnosis is generally owing to overlapping imaging features. This study describes the building of a radiomics nomogram based on clinical data and radiomics signature for the preoperative differentiation of RO from clear cell renal cell carcinoma (ccRCC) on tri-phasic contrast-enhanced CT. Read More

View Article and Full-Text PDF
November 2021

A deep-learning based artificial intelligence (AI) approach for differentiation of clear cell renal cell carcinoma from oncocytoma on multi-phasic MRI.

Clin Imaging 2021 Sep 18;77:291-298. Epub 2021 Jun 18.

Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD, USA. Electronic address:

Purpose: To investigate the diagnostic performance of a deep convolutional neural network for differentiation of clear cell renal cell carcinoma (ccRCC) from renal oncocytoma.

Methods: In this retrospective study, 74 patients (49 male, mean age 59.3) with 243 renal masses (203 ccRCC and 40 oncocytoma) that had undergone MR imaging 6 months prior to pathologic confirmation of the lesions were included. Read More

View Article and Full-Text PDF
September 2021

Active Surveillance for Biopsy Proven Renal Oncocytomas: Outcomes and Feasibility.

Urology 2021 10 1;156:185-190. Epub 2021 Jun 1.

Department of Urology and Kidney Transplantation, Aix-Marseille University, APHM, Conception University Hospital, Marseille, France. Electronic address:

Objectives: To report the outcomes and feasibility of active surveillance (AS) of biopsy-proven renal oncocytomas.

Methods: Multicentric retrospective study (2010-2016) in 6 academic centers that included patients with biopsy-proven renal oncocytomas who were allocated to AS (imperative or elective indication) with a follow-up ≥1 year. Imaging was performed at least once a year, by CT-scan or ultrasound or MRI. Read More

View Article and Full-Text PDF
October 2021

Renal oncocytoma: landscape of diagnosis and management.

BJU Int 2021 12 20;128(6):685-687. Epub 2021 Jun 20.

Division of Surgery and Interventional Science, University College London, London, UK.

View Article and Full-Text PDF
December 2021

Differentiation between renal oncocytomas and chromophobe renal cell carcinomas using dynamic contrast-enhanced computed tomography.

Abdom Radiol (NY) 2021 07 12;46(7):3309-3316. Epub 2021 Mar 12.

Department of Radiology, Affiliated Hospital of Nanjing University of Chinese Medicine, No. 155 Hanzhong Road, Nanjing, 210029, Jiangsu, China.

Purpose: To evaluate the ability of inferior vena cava-lesion-attenuation-difference (ILAD) and lesion-cortex-attenuation-ratio (LCAR) to differentiate renal oncocytomas (RO) from chromophobe renal cell carcinomas (chRCC).

Methods: Retrospective study with analysis of 84 cases of chRCC and 30 cases of RO confirmed by surgical pathology. ILAD was calculated by measuring the difference in Hounsfield units (HU) between the inferior vena cava and the lesion of interest on the same image slice on preoperative CT scan. Read More

View Article and Full-Text PDF

Differential diagnosis of renal oncocytoma and chromophobe renal cell carcinoma using CT features: a central scar-matched retrospective study.

Acta Radiol 2022 Feb 26;63(2):253-260. Epub 2021 Jan 26.

Department of Radiology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, PR China.

Background: Renal oncocytoma (RO) and chromophobe renal cell carcinoma (chRCC) have a common cellular origin and different clinical management and prognosis.

Purpose: To explore the utility of computed tomography (CT) in the differentiation of RO and chRCC.

Material And Methods: Twenty-five patients with RO and 73 patients with chRCC presenting with the central scar were included retrospectively. Read More

View Article and Full-Text PDF
February 2022

Imaging Characterization of Renal Masses.

Medicina (Kaunas) 2021 Jan 8;57(1). Epub 2021 Jan 8.

Radiology Department, Hospital Clinic, University of Barcelona (UB), 08036 Barcelona, Spain.

The detection of a renal mass is a relatively frequent occurrence in the daily practice of any Radiology Department. The diagnostic approaches depend on whether the lesion is cystic or solid. Cystic lesions can be managed using the Bosniak classification, while management of solid lesions depends on whether the lesion is well-defined or infiltrative. Read More

View Article and Full-Text PDF
January 2021

Magnetic resonance diffusion kurtosis imaging in differential diagnosis of benign and malignant renal tumors.

Cancer Imaging 2021 Jan 7;21(1). Epub 2021 Jan 7.

Department of Medical Imaging, Clinical Medical College, Yangzhou University, No 98 West Nantong Road, Yangzhou, 225001, China.

Background: Benign and malignant renal tumors share similar some imaging findings.

Methods: Sixty-six patients with clear cell renal cell carcinoma (CCRCC), 13 patients with renal angiomyolipoma with minimal fat (RAMF) and 7 patients with renal oncocytoma (RO) were examined. For diffusion kurtosis imaging (DKI), respiratory triggered echo-planar imaging sequences were acquired in axial plane (3 b-values: 0, 500, 1000s/mm). Read More

View Article and Full-Text PDF
January 2021

Active surveillance for bilateral renal oncocytomas already resected on one side: a case report.

Urologia 2021 May 8;88(2):122-124. Epub 2020 Dec 8.

Dipartimento di Chirurgia Specialistica, Unità Complessa di Urologia, Ospedale Ca'Foncello, Treviso, Italy.

Introduction: To report our experience of active surveillance of new bilateral masses after left laparoscopic partial nephrectomy for oncocytoma.

Method: A 67-year old man underwent left laparoscopic partial nephrectomy for a renal mass and histology confirmed oncocytoma. At follow-up magnetic resonance imaging (MRI) showed new renal bilateral masses: hence, sonogram-guided percutaneous core renal biopsies were performed confirming the presence of oncocytoma in both kidneys. Read More

View Article and Full-Text PDF

Diagnostic Performance of Contrast-Enhanced Ultrasound (CEUS) in the Evaluation of Solid Renal Masses.

Medicina (Kaunas) 2020 Nov 19;56(11). Epub 2020 Nov 19.

Department of Radiology, Ludwig-Maximilians-University Munich, 81377 Munich, Germany.

Background: The present study aims to evaluate the diagnostic performance of contrast-enhanced ultrasound (CEUS) for discriminating between benign and malignant solid renal masses.

Methods: 18 patients with histopathologically confirmed benign solid renal masses (11 oncocytomas, seven angiomyolipomas) as well as 96 patients with confirmed renal cell carcinoma (RCC) who underwent CEUS followed by radical or partial nephrectomy were included in this single-center study. CEUS examinations were performed by an experienced radiologist (EFSUMB Level 3) and included the application of a second-generation contrast agent. Read More

View Article and Full-Text PDF
November 2020

Histo-molecular differentiation of renal cancer subtypes by mass spectrometry imaging and rapid proteome profiling of formalin-fixed paraffin-embedded tumor tissue sections.

Oncotarget 2020 Nov 3;11(44):3998-4015. Epub 2020 Nov 3.

Department of Biochemistry & Molecular Biology and VILLUM Center for Bioanalytical Sciences, University of Southern Denmark, Odense, Denmark.

Pathology differentiation of renal cancer types is challenging due to tissue similarities or overlapping histological features of various tumor (sub) types. As assessment is often manually conducted outcomes can be prone to human error and therefore require high-level expertise and experience. Mass spectrometry can provide detailed histo-molecular information on tissue and is becoming increasingly popular in clinical settings. Read More

View Article and Full-Text PDF
November 2020

CT-based radiomics for differentiating renal tumours: a systematic review.

Abdom Radiol (NY) 2021 05 2;46(5):2052-2063. Epub 2020 Nov 2.

Department of Medical Imaging Research Office, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.

Purpose: Differentiating renal tumours into grades and tumour subtype from medical imaging is important for patient management; however, there is an element of subjectivity when performed qualitatively. Quantitative analysis such as radiomics may provide a more objective approach. The purpose of this article is to systematically review the literature on computed tomography (CT) radiomics for grading and differentiating renal tumour subtypes. Read More

View Article and Full-Text PDF

Histological differential diagnostics of renal oncocytoma.

Exp Oncol 2020 09;42(3):233-237

Bohomolets National Medical University, Kyiv 01601, Ukraine.

Background: The morbidity rate of kidney cancer has been increasing. Management of patients and their prognosis depend on the specific histological type of tumor. Unfortunately, different renal tumors can have similar histological features, making differential diagnostics challenging. Read More

View Article and Full-Text PDF
September 2020

Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy.

J Cancer 2020 21;11(20):6081-6089. Epub 2020 Aug 21.

Department Hematology, Oncology and Rheumatology, Heidelberg University, Heidelberg, Germany.

While subtyping of the majority of malignant chromophobe renal cell carcinoma (cRCC) and benign renal oncocytoma (rO) is possible on morphology alone, additional histochemical, immunohistochemical or molecular investigations are required in a subset of cases. As currently used histochemical and immunohistological stains as well as genetic aberrations show considerable overlap in both tumors, additional techniques are required for differential diagnostics. Mass spectrometry imaging (MSI) combining the detection of multiple peptides with information about their localization in tissue may be a suitable technology to overcome this diagnostic challenge. Read More

View Article and Full-Text PDF

Dual-Phase 99mTc-MIBI SPECT/CT in the Characterization of Enhancing Solid Renal Tumors: A Single-Institution Study of 147 Cases.

Clin Nucl Med 2020 Oct;45(10):765-770

From the Departments of Nuclear Medicine.

Purpose: The aim of this study was to investigate the value of dual-phase Tc-MIBI SPECT/CT in the differential diagnosis between benign and malignant enhancing solid renal tumors.

Patients And Methods: Totally, 180 patients were imaged with dual-phase Tc-MIBI SPECT/CT, which was performed 30 minutes and 90 minutes after Tc-MIBI administration. Among them, 147 patients with 148 histologically proved solid renal tumors met the selection criteria and were included for the final analysis. Read More

View Article and Full-Text PDF
October 2020

Trans-urethral resection of bladder tumor (TURBT) and radiofrequency ablation of renal tumor: Rare etiologies of chyluria.

Radiol Case Rep 2020 Sep 10;15(9):1579-1583. Epub 2020 Jul 10.

St. Vincent's Medical Center, Bridgeport, CT, USA.

Chyluria is a rare entity which is caused by abnormal communication between the lymphatic system and the urinary tract, which allows the passage of chyle into the urine. Whenever symptomatic, chyluria presents with lower urinary tract symptoms such as dysuria and hematuria. Multiple imaging modalities can aid in diagnosis such as lymphoscintigraphy, retrograde pyelography, CT scan of the abdomen and pelvis, and magnetic resonance imaging. Read More

View Article and Full-Text PDF
September 2020

Small renal masses (≤ 4 cm): differentiation of oncocytoma from renal clear cell carcinoma using ratio of lesion to cortex attenuation and aorta-lesion attenuation difference (ALAD) on contrast-enhanced CT.

Radiol Med 2020 Dec 8;125(12):1280-1287. Epub 2020 May 8.

Section of Radiology, Unit of Surgical Sciences, Department of Medicine and Surgery, Azienda Ospedaliero-Universitaria di Parma, University of Parma, Parma, Italy.

Purpose: We investigate the use of ratio of lesion to cortex (L/C) attenuation and aorta-lesion attenuation difference (ALAD) on multiphase contrast-enhanced CT to help distinguish oncocytoma from clear cell RCC in small renal masses (diameter < 4 cm).

Methods: We retrospectively identified 76 patients that undergo CT before surgery for a suspicious small renal mass between January 2014 and December 2018 with pathological diagnosis of 21 oncocytomas (ROs), 25 clear cell RCCs, 7 chromophobe RCCs, 7 papillary RCCs, 7 multilocular cystic RCCs, 7 angiomyolipomas and 2 leiomyomas. CT attenuation values were obtained for the tumor, the normal renal cortex and the aorta, placing a circular region of interest (ROI) in the same slice by two radiologists, independently. Read More

View Article and Full-Text PDF
December 2020

Aberrant Expression of Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) in Warthin Tumors.

Cancers (Basel) 2020 Apr 29;12(5). Epub 2020 Apr 29.

Institute of Anatomy and Cell Biology, Philipps-Universität Marburg, 35037 Marburg, Germany.

The Warthin tumor represents the second most frequent benign tumor of the parotid gland and is characterized by the presence of oncocytes rich in structurally and functionally altered mitochondria. Next to its role in metabolism, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is also implicated in cellular mitophagy. Immunohistochemistry was carried out on Warthin tumor and normal control (parotid gland with striated ducts) tissues, using anti-GAPDH specific antibodies followed by digital image analysis. Read More

View Article and Full-Text PDF